Article

Structural Basis for a New Mechanism of Inhibition of H I V-1 Integrase Identified by Fragment Screening and Structure-Based Design

Avexa Ltd, Richmond, Australia.
Antiviral chemistry & chemotherapy 04/2011; 21(4):155-68. DOI: 10.3851/IMP1716
Source: PubMed

ABSTRACT

HIV-1 integrase is a clinically validated therapeutic target for the treatment of HIV-1 infection, with one approved therapeutic currently on the market. This enzyme represents an attractive target for the development of new inhibitors to HIV-1 that are effective against the current resistance mutations.
A fragment-based screening method employing surface plasmon resonance and NMR was initially used to detect interactions between integrase and fragments. The binding sites of the fragments were elucidated by crystallography and the structural information used to design and synthesize improved ligands.
The location of binding of fragments to the catalytic core of integrase was found to be in a previously undescribed binding site, adjacent to the mobile loop. Enzyme assays confirmed that formation of enzyme-fragment complexes inhibits the catalytic activity of integrase and the structural data was utilized to further develop these fragments into more potent novel enzyme inhibitors.
We have defined a new site in integrase as a valid region for the structure-based design of allosteric integrase inhibitors. Using a structure-based design process we have improved the activity of the initial fragments 45-fold.

Download full-text

Full-text

Available from: Gregory Paul Savage
    • "Because much attention has been paid to ST inhibitors, the structural factors which affected 3'P inhibitory activity of HIV-1 integrase are still not very clear. Although some HIV-1 integrase X-ray crystal structures have been determined with ligands2223242526, few of them present the core factor which qualifies a compound to inhibit the 3'P step. Therefore, taking a ligand-based approach, the binding affinity of a new molecule might be predicted using computational models derived from known inhibitors and their experimental bioassay values. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, four computational quantitative structure-activity relationship (QSAR) models were built to predict the bioactivity of 3' processing (3'P) inhibitors of HIV-1 integrase. Some 453 inhibitors whose bioactivity values were detected by the radiolabelling method were collected. The molecular structures were represented with MOE descriptors. In total, 21 descriptors were selected for modelling. All inhibitors were divided into a training set and a test set with two methods: (1) by a Kohonen's self-organizing map (SOM); (2) by a random selection. For every training set and test set, a multilinear regression (MLR) analysis and a support vector machine (SVM) were used to establish models, respectively. For the training/test set divided by SOM, the correlation coefficients (r) were over 0.84, and for the training/test set split randomly, the r values were over 0.86. Some molecular properties such as hydrogen bond donor capacity, atomic partial charge properties, molecular refractivity, the number of aromatic bonds and molecular surface area, volume and shape properties played important roles for inhibiting 3' processing step of HIV-1 integrase.
    No preview · Article · Aug 2014 · SAR and QSAR in Environmental Research
  • Source
    • "Due to the lack of exact crystallographic data on the full integrase or integration complex, this mechanism is only a strong hypothesis. Other possible mechanisms should also be considered including the allosteric interaction of inhibitors with the integration complex [96] [97] [98]. Nevertheless, there are several data that have confirmed this approach. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV integrase became an important target for drug development more than twenty years ago. However, progress has been hampered by the lack of assays suitable for high throughput screening, a reliable crystal structure or pharmacophore. Thus, a real breakthrough was only observed in 2007 with the introduction of the first integrase inhibitor, raltegravir, into treatment. To date, the armament of integrase inhibitors is broad and covers several drugs from different classes that are under clinical trials. Among them, quinoline-based compounds and analogues occupy an important place. This review is focused on those compounds that have a quinoline scaffold and attempts to answer the question of whether quinoline is privileged for these activities. In fact, quinoline has been claimed as a privileged structure several times for different fields of activities. A closer look at its structural features may reveal the prerequisites responsible for the popularity of quinoline-based inhibitors of HIV integrase.
    Full-text · Article · Oct 2012 · Current pharmaceutical design
  • Source
    • "The ability to reproducibly generate high quality CCD IN crystals allowed us to generate all complex structures by soaking in the compounds with preformed HIV IN CCD crystals. The protein was crystallized as described previously [10]. Briefly, purified hexa-His core3H protein was concentrated to 5.5 mg/ml in 40 mM Tris pH 8.0, 250 mM NaCl, 30 mM MgCl2 and 5 mM DTT. Drops were set up in SD-2 (IDEX Corp) sitting drop plates using a Phoenix robot (Art Robbins Industries) with 50 µl of crystallant in the reservoir and droplets consisting of 200 nl of the reservoir and 200 nl of the protein sample. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A fragment-based screen against human immunodeficiency virus type 1 (HIV) integrase led to a number of compounds that bound to the lens epithelium derived growth factor (LEDGF) binding site of the integrase catalytic core domain. We determined the crystallographic structures of complexes of the HIV integrase catalytic core domain for 10 of these compounds and quantitated the binding by surface plasmon resonance. We demonstrate that the compounds inhibit the interaction of LEDGF with HIV integrase in a proximity AlphaScreen assay, an assay for the LEDGF enhancement of HIV integrase strand transfer and in a cell based assay. The compounds identified represent a potential framework for the development of a new series of HIV integrase inhibitors that do not bind to the catalytic site of the enzyme.
    Full-text · Article · Jul 2012 · PLoS ONE
Show more